borderline significantP = 0.069
CPB duration was a borderline significant risk factor (β = 0.177, OR = 1.194, 95%CI 0.996–1.462, P = 0.069).
CPB duration was a borderline significant risk factor (β = 0.177, OR = 1.194, 95%CI 0.996–1.462, P = 0.069).
The second vancomycin dosing regimen (0.5 g q6h) showed a trend towards a protective effect compared to the conventional regimen (β = −0.646, OR = 0.524, 95%CI 0.246–1.064, P = 0.082).